ZAI LAB LIMITED Comprehensive Income
ZAI LAB LIMITED (ZLAB) reported Comprehensive Income of -$65.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$65.72M.
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$65.61M.
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$60.36M.
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$42.67M.
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$196.35M.
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$244.21M.
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$322.68M.
- ZAI LAB LIMITED comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$393.96M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$65.72M 10-Q · filed 2026-08-06 | -$131.32M 10-Q · filed 2026-08-06 | -$191.68M derived: sum of 3 quarters · filed 2026-08-06 | -$234.35M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$65.61M 10-Q · filed 2026-05-07 | -$125.97M derived: sum of 2 quarters · filed 2026-05-07 | -$168.63M derived: sum of 3 quarters · filed 2026-05-07 | -$212.31M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$60.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$103.02M derived: sum of 2 quarters · filed 2026-02-26 | -$146.71M derived: sum of 3 quarters · filed 2026-08-06 | -$196.35M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$42.67M 10-Q · filed 2025-11-06 | -$86.35M derived: sum of 2 quarters · filed 2026-08-06 | -$136.00M 10-Q · filed 2025-11-06 | -$195.44M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$43.68M 10-Q · filed 2026-08-06 | -$93.33M 10-Q · filed 2026-08-06 | -$152.77M derived: sum of 3 quarters · filed 2026-08-06 | -$208.94M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$49.65M 10-Q · filed 2026-05-07 | -$109.09M derived: sum of 2 quarters · filed 2026-05-07 | -$165.26M derived: sum of 3 quarters · filed 2026-05-07 | -$241.94M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$59.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$115.61M derived: sum of 2 quarters · filed 2026-02-26 | -$192.28M derived: sum of 3 quarters · filed 2026-02-26 | -$244.21M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$56.17M 10-Q · filed 2025-11-06 | -$132.85M derived: sum of 2 quarters · filed 2025-11-06 | -$184.78M 10-Q · filed 2025-11-06 | -$290.53M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$76.67M 10-Q · filed 2025-08-07 | -$128.60M 10-Q · filed 2025-08-07 | -$234.36M derived: sum of 3 quarters · filed 2026-02-26 | -$307.74M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$51.93M 10-Q · filed 2025-05-08 | -$157.68M derived: sum of 2 quarters · filed 2026-02-26 | -$231.06M derived: sum of 3 quarters · filed 2026-02-26 | -$317.05M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$105.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$179.13M derived: sum of 2 quarters · filed 2026-02-26 | -$265.12M derived: sum of 3 quarters · filed 2026-02-26 | -$322.68M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$73.38M 10-Q · filed 2024-11-12 | -$159.37M derived: sum of 2 quarters · filed 2024-11-12 | -$216.92M 10-Q · filed 2024-11-12 | -$292.56M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$85.99M 10-Q · filed 2024-08-06 | -$143.54M 10-Q · filed 2024-08-06 | -$219.18M derived: sum of 3 quarters · filed 2025-02-27 | -$345.31M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$57.56M 10-Q · filed 2024-05-08 | -$133.19M derived: sum of 2 quarters · filed 2025-02-27 | -$259.32M derived: sum of 3 quarters · filed 2025-02-27 | -$366.93M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | -$75.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$201.76M derived: sum of 2 quarters · filed 2025-02-27 | -$309.37M derived: sum of 3 quarters · filed 2025-02-27 | -$393.96M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$126.13M 10-Q · filed 2023-11-07 | -$233.74M derived: sum of 2 quarters · filed 2023-11-07 | -$318.32M 10-Q · filed 2023-11-07 | -$538.67M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | -$107.61M 10-Q · filed 2023-08-07 | -$192.19M 10-Q · filed 2023-08-07 | -$412.54M derived: sum of 3 quarters · filed 2024-02-27 | -$507.21M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$84.59M 10-Q · filed 2023-05-09 | -$304.93M derived: sum of 2 quarters · filed 2024-02-27 | -$399.60M derived: sum of 3 quarters · filed 2024-02-27 | -$568.17M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | -$220.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$315.02M derived: sum of 2 quarters · filed 2024-02-27 | -$483.58M derived: sum of 3 quarters · filed 2024-02-27 | -$713.59M 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$94.67M 10-Q · filed 2022-11-09 | -$263.24M derived: sum of 2 quarters · filed 2022-11-09 | -$493.25M 10-Q · filed 2022-11-09 | -$581.40M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$168.56M 10-Q · filed 2022-08-09 | -$398.57M 10-Q · filed 2022-08-09 | -$486.73M derived: sum of 3 quarters · filed 2023-03-01 | -$560.37M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | -$230.01M 10-Q · filed 2022-05-10 | -$318.17M derived: sum of 2 quarters · filed 2023-03-01 | -$391.81M derived: sum of 3 quarters · filed 2023-03-01 | -$473.61M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$88.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$161.80M derived: sum of 2 quarters · filed 2023-03-01 | -$243.60M derived: sum of 3 quarters · filed 2023-03-01 | -$288.05M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$73.64M 10-Q · filed 2021-11-09 | -$155.44M derived: sum of 2 quarters · filed 2021-11-09 | -$199.89M 10-Q · filed 2021-11-09 | -$248.67M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | -$81.80M 10-Q · filed 2021-08-09 | -$126.25M 10-Q · filed 2021-08-09 | -$175.03M derived: sum of 3 quarters · filed 2022-03-01 | -$236.65M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | -$44.45M 10-Q · filed 2021-05-10 | -$93.23M derived: sum of 2 quarters · filed 2022-03-01 | -$154.85M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | -$48.78M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | -$110.40M derived: sum of 2 quarters · filed 2022-03-01 | -$193.11M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$61.62M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | -$144.33M 6-K · filed 2020-01-21 | |||
| 2019-06-30 | -$82.71M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | -$62.37M derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | -$136.86M 10-K · filed 2021-03-01 | -$136.86M 20-F · filed 2019-03-29 | ||
| 2018-09-30 | -$74.49M 6-K · filed 2020-01-21 | ||||
| 2017-12-31 | -$49.24M 20-F · filed 2020-04-29 | -$49.24M 20-F · filed 2018-04-30 | |||
| 2016-12-31 | -$18.12M 20-F · filed 2019-03-29 | -$38.11M 20-F · filed 2018-04-30 | |||
| 2015-12-31 | -$18.12M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |